These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7380909)

  • 1. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
    Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
    J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
    Strong JM; Kinney YE; Branfman AR; Cysyk RL
    Cancer Treat Rep; 1979 May; 63(5):775-80. PubMed ID: 455314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
    Lankelma J; Penders PG; Leyva A; Pinedo HM
    Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
    [No Abstract]   [Full Text] [Related]  

  • 4. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
    Roboz J; Suzuki R; Rose E
    J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
    Kensler TW; Jayaram HN; Cooney DA
    J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
    Erlichman C; Strong JM; Chabner BA
    Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
    Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
    Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
    Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
    Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
    Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
    Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
    Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
    Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
    Casper ES; Baselga J; Smart TB; Magill GB; Markman M; Ranhosky A
    Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
    Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
    Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
    Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
    Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
    Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
    Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.